A review study to evaluate mannitol-assisted prophylaxis and treatment for acute promyelocytic leukemia

Retrospective study on mannitol-assisted prophylaxis and treatment for acute promyelocytic leukemia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN94954912

Enrollment

100

Registered

2014-01-20

Start date

1998-01-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

APL CNS relapse Cancer Acute promyelocytic leukaemia [PML]

Interventions

The study involved two groups of APL patients receiving different mannitol-assisted regimens: 1. Patients with CNS relapse received intrathecal chemotherapy plus mannitol-assisted arsenic trioxide (AT

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Any age APL patients, with either risks of central nervous system (CNS) relapse or already diagnosed with CNS relapse 2. Patients agreed to receive the prophylaxis or treatment

Exclusion criteria

Exclusion criteria: 1. Previous history of severe cardiovascular disease (coronary arterial disease, stroke, etc) 2. Severe chronic disease with poor prognosis (liver disease, kidney disease, etc) 3. Illegal drug use or chronic alcoholism 4. Physical limitations, mental or intellectual disabilities 5. Any condition that may affect the development of this trial

Design outcomes

Primary

Measure	Time frame
1. Disease-free survival 2. Overall survival	—

Secondary

Measure	Time frame
1. Cerebrospinal fluid (CSF) ATO concentrations 2. CSF tests of APL burden 3. Drug side effects evaluation	—

Countries

China

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026